Roche has entered into a definitive agreement  to acquire Mirus Bio Corp. for $125 million. Mirus Bio is a privately owned company based in Madison, WI, focused on the discovery and development of RNAi delivery technologies.     Under the terms of the agreement, Roche will maintain an RNAi research site in Madison. Mirus’ transfection reagents business will be divested into a standalone business called Mirus Bio LLC. Employees will be offered a transition into their respective business...